Protagen and GeneBio Sign Distribution Agreement for Modiro®
News May 30, 2008
Protagen AG and Geneva Bioinformatics (GeneBio) SA announced a distribution agreement that allows GeneBio to distribute Protagen’s Modiro, a software tool enabling rapid and automated detection of true post-translational modifications in MS/MS datasets.
Under the terms of the agreement, GeneBio will distribute the Modiro package on a global basis; at the same time, GeneBio and Protagen will collaborate closely in order to seamlessly link the Modiro functionalities to GeneBio’s Phenyx software platform for MS data analysis.
Post-translational protein modifications modulate the activity of many proteins and the in-depth analysis of these changes is of growing importance in the research and development of new drug candidates.
Modiro enables researchers to identify significantly more of these crucial modifications using existing mass-spectrometry data. In addition, the automated identification of PTMs by Modiro significantly reduces time and efforts in protein analyses.
Developed in collaboration with the Swiss Institute of Bioinformatics (SIB), Phenyx is GeneBio’s renowned software platform for the identification and characterization of proteins and peptides from mass spectrometry data.
The Phenyx platform is designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment via a customizable architecture and an user friendly interface.
“We are very excited about this collaboration with GeneBio and believe it will help to bring Modiro to wide range of new customers,” said Dr. Christoph Huls, CEO of Protagen.
“We are well aware of the reputation of both GeneBio and Phenyx within the industry and feel that our combined efforts will help to establish Modiro as the gold-standard for PTM analysis. In addition, we look forward to working with the GeneBio team in order to enhance both the Modiro and Phenyx platform.”
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE
In recent years, numerous studies have shown that people who don't get enough sleep are at greater risk of stroke and heart attack. A study found that people who sleep fewer than 7 hours per night have lower blood levels of three physiological regulators, or microRNAs, which influence gene expression and play a key role in maintaining vascular health.